Tissue engineering of replacement skin: the crossroads of biomaterials, wound healing, embryonic development, stem cells and regeneration.
Advanced therapies combating acute and chronic skin wounds are likely to be brought about using our knowledge of regenerative medicine coupled with appropriately tissue-engineered skin substitutes. At the present time, there are no models of an artificial skin that completely replicate normal uninjured skin. Natural biopolymers such as collagen and fibronectin have been investigated as potential sources of biomaterial to which cells can attach. The first generation of degradable polymers used in tissue engineering were adapted from other surgical uses and have drawbacks in terms of mechanical and degradation properties. This has led to the development of synthetic degradable gels primarily as a way to deliver cells and/or molecules in situ, the so-called smart matrix technology. Tissue or organ repair is usually accompanied by fibrotic reactions that result in the production of a scar. Certain mammalian tissues, however, have a capacity for complete regeneration without scarring; good examples include embryonic or foetal skin and the ear of the MRL/MpJ mouse. Investigations of these model systems reveal that in order to achieve such complete regeneration, the inflammatory response is altered such that the extent of fibrosis and scarring is diminished. From studies on the limited examples of mammalian regeneration, it may also be possible to exploit such models to further clarify the regenerative process. The challenge is to identify the factors and cytokines expressed during regeneration and incorporate them to create a smart matrix for use in a skin equivalent. Recent advances in the use of DNA microarray and proteomic technology are likely to aid the identification of such molecules. This, coupled with recent advances in non-viral gene delivery and stem cell technologies, may also contribute to novel approaches that would generate a skin replacement whose materials technology was based not only upon intelligent design, but also upon the molecules involved in the process of regeneration.
Metcalfe
Anthony D
AD
UK Centre for Tissue Engineering, Faculty of Life Sciences, University of Manchester, 3.239 Stopford Building, Oxford Road, Manchester, UK
Ferguson
Mark W J
MW
D000818:Animals; D001672:Biocompatible Materials; D002921:Cicatrix / Q000517:prevention & control; D003094:Collagen; D003167:Complement Activation; D016207:Cytokines / Q000008:administration & dosage; D047108:Embryonic Development; D005353:Fibronectins; D006133:Growth Substances / Q000008:administration & dosage; D006801:Humans; D051379:Mice; D012038:Regeneration / Q000502:physiology; D012867:Skin / Q000293:injuries; D017768:Skin, Artificial; D013234:Stem Cells / Q000166:cytology; D013917:Thrombin / Q000378:metabolism; D023822:Tissue Engineering / Q000379:methods* / Q000639:trends; D016212:Transforming Growth Factor beta / Q000378:metabolism; D014945:Wound Healing
D001672:Biocompatible Materials; D016207:Cytokines; D005353:Fibronectins; D006133:Growth Substances; D016212:Transforming Growth Factor beta; D003094:Collagen; D013917:Thrombin